ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1370	National Cancer Institute	Html	en	Colorectal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for colorectal cancer.	adenomas 0.617512 advanced proximal neoplasia 0.563212 study 0.677803 mortality reduction 0.57851 advanced neoplasia 0.56302 CRC mortality reduction 0.544829 colonoscopy screening 0.603021 lesions 0.531993 occult blood screening 0.64042 CRC mortality difference 0.548807 CRC incidence rates 0.553335 Engl J Med 0.6404 CRC mortality 0.70138 CRC cases 0.529979 annual FOBT screening 0.529584 faecal occult blood 0.779217 Ann Intern Med 0.763728 complete colonoscopy 0.535099 colorectal cancer screening 0.676312 colonoscopy 0.785471 positive test 0.545148 colorectal neoplasia 0.540206 colorectal cancer incidence 0.537416 detection 0.55517	colorectal cancer 0.99103 CRC screening 0.62285 Abstract 0.639242 Screening Colonoscopy Program 0.575204 patients 0.584805 occult blood testing 0.542273 colonoscopy study 0.538236 CRC incidence 0.62219 systematic review 0.578714 lower CRC mortality 0.560554 virtual colonoscopy 0.591165 CRC screening program 0.568518 FIT 0.57064 Colorectal cancer mortality 0.560865 negative colonoscopy results 0.549077 concurrently performed colonoscopy 0.531966 fecal occult blood 0.884171 CRC 0.781593 sigmoidoscopy versus colonoscopy 0.551587 colorectal cancer diagnosis 0.530522 distal colon 0.542283 occult blood test 0.71312 sensitivity 0.537205	CLICK HERE
1406	National Cancer Institute	Html	en	Endometrial Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.	underwent endometrial biopsy 0.596006 exhibit similar risk 0.466243 endometrial thickness cutoff 0.594653 endometrial carcinoma 0.559295 asymptomatic women 0.56298 markedly increased risk 0.46896 endometrial biopsy 0.602665 TVU 0.506165 threshold value 0.468657 postmenopausal uterine bleeding 0.47677 hormone therapy study 0.462599 postmenopausal hormone therapy. 0.491288 additional risk factors 0.461801 endometrial cavity access. 0.584206 high survival rates 0.463126 lower survival rates 0.458386 endometrial thickness 0.608159 endometrial hyperplasia 0.560125 white women 0.528892 combination estrogen-progesterone therapy 0.467831 endometrial cancer 0.93723 U.S. women 0.465931 abnormal pathologic biopsy 0.461543 black women 0.483703 women 0.713028	unopposed estrogen therapy 0.4738 endometrial cancer. 0.591335 nonpolyposis colorectal cancer 0.479683 endometrial polyps 0.561278 endometrial aspiration 0.621101 Measuring endometrial thickness 0.597601 estrogen therapy 0.49246 Cancer Survival Study 0.480563 tamoxifen increase patients 0.459307 National Cancer Institute 0.477348 hormone therapy 0.561237 endometrial biopsy specimens 0.590423 endometrial cancer incidence 0.661899 African American women 0.535123 invasive gynecologic cancer 0.486102 advanced-stage disease 0.478186 breast cancer 0.469124 asymptomatic postmenopausal women 0.5655 primary endometrial cancer 0.608017 Project P-1 trial 0.458556 endometrial abnormalities 0.576298 National Surgical Adjuvant 0.459038 African American women. 0.461116 mean age 0.461702	CLICK HERE
1450	National Cancer Institute	Html	en	Esophageal Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for esophageal cancer.	population-based case-controlled study 0.533968 symptomatic gastroesophageal reflux 0.581421 columnar-lined esophagus 0.552922 curable neoplasms 0.466702 Barrett esophagus 0.931446 Gastric cardia adenocarcinoma 0.596066 lower esophageal sphincter 0.581561 standard histological evaluation 0.515998 gastroesophageal reflux 0.731721 squamous cell cancer 0.550703 surveillance method 0.472755 risk factors 0.526039 annual endoscopy 0.479023 esophageal squamous cell 0.594095 gastric acid production 0.530474 -relaxing drugs 0.467279 patients 0.488679 Barrett esophagus. 0.572924 GERD 0.55771 esophageal cancer incidence 0.58939 esophageal adenocarcinoma 0.818574 esophageal adenocarcinoma. 0.53156 human papillomavirus 0.478898 new cases 0.479464	gastroesophageal reflux disease 0.686421 low risk 0.472905 esophageal cancer 0.594243 H. pylori infections 0.535834 infection persisted. 0.473995 incidence rate ratio 0.524115 reflux esophagitis 0.501118 surgical resection 0.524265 low-grade dysplasia 0.493637 effective surveillance protocol 0.524901 surveillance endoscopy 0.490968 reflux symptoms 0.502651 high-grade dysplasia 0.535845 important epidemiological difference 0.530091 strong association 0.468389 expert gastrointestinal endoscopists 0.517855 duodenal ulcers 0.473231 risk factor 0.481047 Western countries 0.470134 successful resection 0.474238 cancer mortality. 0.469146 gastric infection 0.4806 risk 0.536679 intramucosal carcinoma 0.47033	CLICK HERE
1466	National Cancer Institute	Html	en	Penile Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of penile cancer.	penile shaft 0.625965 lower prevalence 0.447004 disease stage 0.456978 odds ratio 0.446539 infected primary lesion 0.547017 PDQ cancer information 0.772684 poorly differentiated tumors 0.538507 clinical trials 0.807326 observational studies 0.567664 cancer information summary 0.707707 breast cancer prevention 0.552706 bilateral inguinal lymph 0.695554 penile HPV 0.678754 NCI’s PDQ 0.530402 PDQ Adult Treatment 0.603184 NCI PDQ cancer 0.668979 stage IV cancer 0.495897 lymph nodes 0.744697 regional inguinal lymph 0.679281 human papillomavirus 0.609539 positive lymph nodes 0.642063 penile cancer. 0.820523 single case 0.4576 antibiotic therapy 0.431816 node metastasis 0.456545	United States 0.583912 new drugs 0.43228 decreased risk 0.457358 microscopic node metastases 0.575056 node dissection 0.478206 prophylactic lymphadenectomy 0.435367 penile cancer 0.96059 National Cancer Institute 0.555757 distant metastases 0.467783 PDQ documents 0.502265 case series studies 0.559492 precursor lesions progress 0.546799 local control 0.438046 Bowen disease 0.435373 inguinal lymph node 0.850704 adjunctive inguinal dissection 0.622563 male newborn circumcision 0.57819 invasive penile cancer. 0.789576 case reports 0.439988 surgical techniques 0.438147 bilateral ilioinguinal dissection 0.579916 confidence interval 0.450369 Inguinal adenopathy 0.494134 human papillomavirus DNA 0.562566	CLICK HERE
1572	National Cancer Institute	Html	en	Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for ovarian, fallopian tube, and primary peritoneal cancers.	cancer treatment 0.488772 primary peritoneal cancers 0.500293 ongoing clinical trials 0.488493 following PDQ summaries 0.549415 PDQ cancer information 0.706697 false-negative test result 0.485124 fallopian tube cancer 0.565282 primary peritoneal cancer 0.815712 clinical trials 0.639646 test result 0.547906 Peritoneal Cancer Prevention 0.54551 cancer information summary 0.620799 PDQ Ovarian 0.537752 clinical trial 0.497999 breast cancer prevention 0.513915 ovarian cancer 0.852752 false-positive test result 0.536437 cancer patients 0.484043 latest published information 0.494395 peritoneal cancer form 0.545913 NCI’s PDQ 0.505993 cancer symptoms 0.504824 NCI PDQ cancer 0.581936 tests 0.532273	certain types 0.48682 black women 0.481021 PDQ Screening 0.526415 peritoneal cancer screening 0.608486 cancer prevention 0.549601 screening tests 0.485985 Cancer Information Service 0.531657 fallopian tube 0.68704 Prevention Editorial Board 0.543082 treatment clinical trials 0.485965 National Cancer Institute 0.650104 PDQ documents 0.496817 cancer doctors 0.479641 new treatment 0.493333 Cancer screening trials 0.564141 Ovarian epithelial cancer 0.582644 Cancer Care page 0.517342 PDQ database 0.501449 PDQ summary 0.536253 fallopian tubes 0.578652 cancer information summaries 0.539976 health professional versions 0.477788 comprehensive cancer information 0.539707 cancer 0.983489	CLICK HERE
1983	National Cancer Institute	Html	es	Tratamiento de los tumores embrionarios del sistema nervioso central infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del meduloblastoma infantil, los tumores embrionarios distintos del meduloblastoma y los tumores pineales infantiles.	meduloblastoma wnt 0.448042 primitive neuroectodermal tumors 0.463972 Kool M 0.408951 tumores wnt 0.418547 prognostic factors 0.423834 germline mutations 0.4087 with medulloblastoma harboring 0.411601 with medulloblastoma receiving 0.411471 early childhood medulloblastoma 0.42493 childhood medulloblastoma 0.434401 meduloblastomas shh 0.413706 Rutkowski S 0.412968 Clin Pract Oncol 0.409953 with carboplatin 0.411606 with localized medulloblastoma 0.410611 Natl Cancer Inst 0.412552 vía wnt 0.411172 with retinoblastoma during 0.417144 Medulloblastoma with extensive 0.410624 Acta Neuropathol 0.421932 Boyett JM 0.420388 Children's Cancer 0.444511 Lancet Oncol 0.408704 medulloblastoma subtypes with 0.411732 subtipo shh 0.409562	meduloblastomas wnt 0.413294 Remke M 0.416131 tumores shh 0.419097 Neuro Oncol 0.413263 Pediatr Blood Cancer 0.465506 Childrens Cancer Group 0.412973 neuroectodermal tumors treated 0.41729 with medulloblastoma 0.429537 Med Genet 0.409674 Clin Oncol 0.618048 sistema nervioso central 0.455844 with supratentorial primitive 0.416554 pediatric medulloblastoma 0.410979 Children's Cancer Group 0.43162 von hoff k 0.413579 tumors treated with 0.41728 término tumor 0.409479 tumores embrionarios 0.947028 Kingdom Children Cancer 0.420872 vía shh 0.424313 children's oncology group 0.440874 Children's Cancer Study 0.422483 molecular subgroups 0.410404 Cancer Study Group 0.41491	CLICK HERE
3453	National Cancer Institute	Html	es	Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre la preparación necesaria por parte de los proveedores de atención de la salud, los pacientes y sus familias para la transición a la atención del cáncer avanzado en la etapa final de la vida.	health care spending 0.331274 Zimmermann C 0.347816 Burman D 0.32527 posibles factores 0.333049 Ewer MS 0.322761 cancer care near 0.391306 creciente número 0.323261 Sin embargo 0.941022 American Cancer Society 0.434589 etapa efv 0.333862 Health Care Brief 0.329424 fase ii 0.322051 Swami N 0.348223 care providers 0.323463 intensive care unit 0.365314 Cancer Care Outcomes 0.349727 coping with cancer 0.340049 quimioterapia paliativa 0.367064 cancer care 0.411213 Early palliative care 0.33009 Landrum MB 0.323564 Dartmouth Institute 0.324797 Estados Unidos 0.323783 Support Care 0.43154 mayores gastos 0.34678	Med Care 0.326126 patients with 0.439314 end-of-life care 0.465368 good death 0.325189 Care Cancer 0.418414 Cancer Facts 0.334548 fase i 0.325785 palliative care 0.349857 cardiac arrest 0.325245 Dartmouth Atlas 0.325161 ill patients with 0.328355 cardiopulmonary resuscitation 0.351378 medical intensive care 0.329231 care intensity 0.323054 beneficiaries dying with 0.321915 Clinical Practice 0.32872 forma favorable calidad 0.324109 alta calidad 0.387852 Health Policy 0.327199 health care 0.342416 Intern Med 0.355877 Clin Oncol 0.402042 Arch Intern Med 0.354168 respiración mecánica 0.42963	CLICK HERE
3456	National Cancer Institute	Html	es	Acupuntura (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre la acupuntura como tratamiento para las personas con cáncer o trastornos relacionados con esta enfermedad.	acupuntura forma 0.644774 Centro Nacional 0.425173 causa reacciones 0.422733 New Hampshire Avenue 0.41766 acupuntos correctos 0.426568 causa hinchazón 0.417784 Drug Administration 0.410869 neuropatía periférica 0.548649 NCI Best Case 0.428652 datos bibliográficos pubmed 0.418907 largo plazo 0.414083 National Cancer Institute 0.420958 siglo xviii 0.41833 siguientes riesgos 0.413128 PDQ Acupuntura 0.568448 acupuntura ayuda 0.53948 Instituto Nacional 0.496395 numerosos informes 0.41497 National Certification Commission 0.424144 Salud Complementaria 0.436282 Visuals Online 0.412814	náuseas matutinas 0.436773 mamaEl linfedema 0.418357 complementarias revisa 0.41658 sistema nervioso central 0.511178 Physician Data Query 0.473664 Medicina Oriental 0.41709 Estados Unidos 0.901304 Comisión Nacional 0.410413 libre uso 0.418723 Oriental Medicine 0.412484 distintos resultados 0.413109 cabo estudios 0.47129 piel agujas 0.436066 página manejo 0.412054 ¿El tratamiento 0.424697 ¿Los beneficios 0.410887 juntos cam 0.410417 qi causa dolor 0.459263 Series Program 0.410794 medicina complementaria 0.788071 Institutos Nacionales 0.521236	CLICK HERE
3519	National Cancer Institute	Html	en	Research Team Members	Information about the different types of experts involved in designing and running a clinical trial.	treatment 0.240173 Typical team members 0.477277 data management 0.339957 records 0.222317 Staff physician 0.322575 concept 0.2227 aspects 0.224933 Institutional Review Board 0.455886 study monitoring 0.329306 Treats patients 0.324814 skills 0.22687 presentation 0.223824 Supervises data collection 0.479065 responsibilities 0.228481 recruitment 0.225467 course 0.246736 health care providers 0.443729 Works 0.240321 audits 0.222243	research nurse 0.569926 final data analysis 0.435286 clinical trial 0.945844 Provides data 0.334954 approval 0.227398 different sites 0.354975 monitoring agencies 0.324055 Assesses 0.227864 Data manager 0.339195 different types 0.351452 Communicates 0.231534 principal investigator 0.901171 person 0.339796 quality assurance 0.332626 Educates staff 0.334468 IRB 0.235474 Designing 0.224461 informed consent process 0.715664 experts 0.226806	CLICK HERE
16711	National Cancer Institute	Html	null	Iniciativa de Respuestas Excepcionales: Preguntas y respuestas	El Instituto Nacional del Cáncer (NCI) emprendió la Iniciativa de Respuestas Excepcionales a fin de entender la base molecular de los tumores en pacientes de cáncer que responden en forma excepcional al tratamiento, principalmente quimioterapia.			CLICK HERE